#Canada #Laval #Bausch Health #Knoa Pharma #Michael Goettler

Michael Goettler Steps Down from Bausch Health Board

On July 1, 2026, Bausch Health Companies Inc. made a significant announcement regarding a key change in its Board of Directors. Michael Goettler, a distinguished member of the board, has officially stepped down, effective June 30, 2026. This decision comes as Goettler is set to take on a new role as the President and Chief Executive Officer of Knoa Pharma LLC.

In the statement released by Bausch Health, John A. Paulson, the Chairperson of the Board, expressed gratitude for Goettler’s dedicated service. He noted, “We thank Michael for his valued service and wish him the best in his new role.” This remarks highlight the respect and appreciation that the board has for Goettler's contributions to the company during his tenure.

Goettler's departure from Bausch Health was clarified to be unrelated to any internal disagreements regarding company policies or practices. This assures stakeholders that the transition is amicable and underlines the focus on his forthcoming responsibilities at Knoa Pharma LLC.

About Bausch Health Companies Inc.

Bausch Health is a prominent global pharmaceutical company based in Laval, Quebec, known for its dedication to improving healthcare outcomes. The enterprise primarily operates in sectors like gastroenterology, dermatology, and eye health, and is recognized for products developed through its major partnership with Bausch + Lomb Corporation.

The company's mission is to enhance health outcomes across various health domains, underpinned by a commitment to innovation and community trust. Their portfolio not only addresses essential healthcare needs but also aims to elevate patient experiences more broadly.

As Bausch Health continues its operations, the company is expected to navigate this transition while maintaining its focus on growth and product development across its diverse therapeutic areas. With Goettler stepping into a new leadership role at Knoa Pharma, both companies stand to benefit from his extensive experience and vision.

This leadership shift at Bausch Health occurs amidst a landscape of continuous change in the pharmaceutical industry, where agility and strategic leadership are crucial for navigating complex challenges. As the company adapts to these changes, stakeholders are encouraged to stay informed about further developments within Bausch Health and the pharmaceutical sector.

For those interested in following Bausch Health’s trajectory post-Goettler, they can find more information through the company’s official channels or by visiting their website. The commitment to delivering better health care outcomes remains a priority, even as leadership transitions take place.

In closing, Michael Goettler's journey from Bausch Health to Knoa Pharma represents a significant professional progression. His experience and leadership skills will undoubtedly be instrumental in his new role, while Bausch Health continues to advance its mission in the pharmaceutical industry.